Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Other Non-Current Assets (2022 - 2025)

BioXcel Therapeutics has reported Other Non-Current Assets over the past 4 years, most recently at $87000.0 for Q1 2025.

  • Quarterly results put Other Non-Current Assets at $87000.0 for Q1 2025, changed 0.0% from a year ago — trailing twelve months through Mar 2025 was $87000.0 (changed 0.0% YoY), and the annual figure for FY2024 was $87000.0, changed 0.0%.
  • Other Non-Current Assets for Q1 2025 was $87000.0 at BioXcel Therapeutics, roughly flat from $87000.0 in the prior quarter.
  • Over the last five years, Other Non-Current Assets for BTAI hit a ceiling of $965000.0 in Q1 2022 and a floor of $87000.0 in Q2 2023.
  • Median Other Non-Current Assets over the past 4 years was $87000.0 (2023), compared with a mean of $412384.6.
  • Biggest five-year swings in Other Non-Current Assets: crashed 90.59% in 2023 and later changed 0.0% in 2024.
  • BioXcel Therapeutics' Other Non-Current Assets stood at $925000.0 in 2022, then crashed by 90.59% to $87000.0 in 2023, then changed by 0.0% to $87000.0 in 2024, then changed by 0.0% to $87000.0 in 2025.
  • The last three reported values for Other Non-Current Assets were $87000.0 (Q1 2025), $87000.0 (Q4 2024), and $87000.0 (Q3 2024) per Business Quant data.